Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2019 | Molecularly-guided treatment of advanced NSCLC: ALK inhibitor sequencing

Alice Tsang Shaw • 3 Jul 2019
ELCC 2019
Lung Cancer Non-Small Cell Lung Cancer Alectinib Brigatinib Ceritinib Crizotinib Lorlatinib

Alice Tsang Shaw, MD, PhD, Massachusetts General Hospital, Boston, MA, discusses the importance of screening for genetic alterations when treating patients with advanced non-small cell lung cancer (NSCLC). She explains how the sequencing of ALK inhibitors could be molecularly guided. This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

More from Alice Tsang Shaw

2:05
Updates from the PROFILE 1001 study
Alice Tsang Shaw • 16 Apr 2019

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals